» Articles » PMID: 32980855

βCysteine 93 in Human Hemoglobin: a Gateway to Oxidative Stability in Health and Disease

Overview
Journal Lab Invest
Specialty Pathology
Date 2020 Sep 27
PMID 32980855
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

βcysteine 93 residue plays a key role in oxygen (O)-linked conformational changes in the hemoglobin (Hb) molecule. This solvent accessible residue is also a target for binding of thiol reagents that can remotely alter O affinity, cooperativity, and Hb's sensitivity to changes in pH. In recent years, βCys93 was assigned a new physiological role in the transport of nitric oxide (NO) through a process of S-nitrosylation as red blood cells (RBCs) travel from lungs to tissues. βCys93 is readily and irreversibly oxidized in the presence of a mild oxidant to cysteic acid, which causes destabilization of Hb resulting in improper protein folding and the loss of heme. Under these oxidative conditions, ferryl heme (HbFe), a higher oxidation state of Hb is formed together with its protein radical (HbFe). This radical migrates to βCys93 and interacts with other "hotspot" amino acids that are highly susceptible to oxidative modifications. Oxidized βCys93 may therefore be used as a biomarker of oxidative stress, reflecting the deterioration of Hb within RBCs intended for transfusion or RBCs from patients with hemoglobinopathies. Site specific mutation of a redox active amino acid(s) to reduce the ferryl heme or direct chemical modifications that can shield βCys93 have been proposed to improve oxidative resistance of Hb and may offer a protective therapeutic strategy.

Citing Articles

Biopreservation and reversal of oxidative injury during blood storage by a novel curcumin-based gel formulation.

Hicks W, Jana S, Kassa T, Prince R, Cabrales P, Friedman J Sci Rep. 2024; 14(1):31441.

PMID: 39733159 PMC: 11682427. DOI: 10.1038/s41598-024-82943-1.


Biopreservation and Reversal of Oxidative Injury During Blood Storage by a Novel Curcumin-based Gel Formulation.

Hicks W, Jana S, Kassa T, Prince R, Cabrales P, Friedman J Res Sq. 2024; .

PMID: 38766242 PMC: 11100889. DOI: 10.21203/rs.3.rs-4277591/v1.


Glutathione Non-Covalent Binding Sites on Hemoglobin and Major Glutathionylation Target betaCys93 Are Conservative among Both Hypoxia-Sensitive and Hypoxia-Tolerant Mammal Species.

Anashkina A, Simonenko S, Orlov Y, Petrushanko I Int J Mol Sci. 2024; 25(1).

PMID: 38203223 PMC: 10778717. DOI: 10.3390/ijms25010053.


How Nitric Oxide Hindered the Search for Hemoglobin-Based Oxygen Carriers as Human Blood Substitutes.

Samaja M, Malavalli A, Vandegriff K Int J Mol Sci. 2023; 24(19).

PMID: 37834350 PMC: 10573492. DOI: 10.3390/ijms241914902.


NO and Heme Proteins: Cross-Talk between Heme and Cysteine Residues.

Verde C, Giordano D, Bruno S Antioxidants (Basel). 2023; 12(2).

PMID: 36829880 PMC: 9952723. DOI: 10.3390/antiox12020321.


References
1.
Perutz M . Stereochemistry of cooperative effects in haemoglobin. Nature. 1970; 228(5273):726-39. DOI: 10.1038/228726a0. View

2.
Cheng Y, Shen T, Simplaceanu V, Ho C . Ligand binding properties and structural studies of recombinant and chemically modified hemoglobins altered at beta 93 cysteine. Biochemistry. 2002; 41(39):11901-13. DOI: 10.1021/bi0202880. View

3.
Alayash A . Mechanisms of Toxicity and Modulation of Hemoglobin-based Oxygen Carriers. Shock. 2017; 52(1S Suppl 1):41-49. PMC: 5934345. DOI: 10.1097/SHK.0000000000001044. View

4.
Khan I, Dantsker D, Samuni U, Friedman A, Bonaventura C, Manjula B . Beta 93 modified hemoglobin: kinetic and conformational consequences. Biochemistry. 2001; 40(25):7581-92. DOI: 10.1021/bi010051o. View

5.
Boykins R, Buehler P, Jia Y, Venable R, Alayash A . O-raffinose crosslinked hemoglobin lacks site-specific chemistry in the central cavity: structural and functional consequences of beta93Cys modification. Proteins. 2005; 59(4):840-55. DOI: 10.1002/prot.20453. View